KR20100068287A - 폐경기 전 여성의 에스트로겐 의존성 질환의 치료 - Google Patents

폐경기 전 여성의 에스트로겐 의존성 질환의 치료 Download PDF

Info

Publication number
KR20100068287A
KR20100068287A KR1020107008404A KR20107008404A KR20100068287A KR 20100068287 A KR20100068287 A KR 20100068287A KR 1020107008404 A KR1020107008404 A KR 1020107008404A KR 20107008404 A KR20107008404 A KR 20107008404A KR 20100068287 A KR20100068287 A KR 20100068287A
Authority
KR
South Korea
Prior art keywords
sts
administration
gnrh
progestin
estrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107008404A
Other languages
English (en)
Korean (ko)
Inventor
에르네스뜨 루메이
쟝-삐에르 고떼랑
Original Assignee
쁘레글렘 에스.아.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쁘레글렘 에스.아. filed Critical 쁘레글렘 에스.아.
Publication of KR20100068287A publication Critical patent/KR20100068287A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020107008404A 2007-09-17 2008-09-04 폐경기 전 여성의 에스트로겐 의존성 질환의 치료 Ceased KR20100068287A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96010907P 2007-09-17 2007-09-17
US60/960,109 2007-09-17

Publications (1)

Publication Number Publication Date
KR20100068287A true KR20100068287A (ko) 2010-06-22

Family

ID=40468492

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107008404A Ceased KR20100068287A (ko) 2007-09-17 2008-09-04 폐경기 전 여성의 에스트로겐 의존성 질환의 치료

Country Status (7)

Country Link
US (1) US20100204146A1 (enExample)
EP (1) EP2207544A2 (enExample)
JP (1) JP5543920B2 (enExample)
KR (1) KR20100068287A (enExample)
BR (1) BRPI0817045A2 (enExample)
CA (1) CA2698814A1 (enExample)
WO (1) WO2009037539A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160076556A (ko) 2014-12-23 2016-07-01 주식회사 젬백스앤카엘 난소 기능 보존용 펩티드 및 이를 포함하는 조성물

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2647378A1 (en) 2012-04-05 2013-10-09 PregLem S.A. Steroid sulfatase inhibitor regimen for the treatment of endometriosis
EP2647379A1 (en) 2012-04-05 2013-10-09 PregLem S.A. Combined use of a steroid sulfatase inhibitor for the treatment of endometriosis
US9522154B2 (en) 2013-03-14 2016-12-20 Laboratoire Hra-Pharma Method for scheduling ovulation
KR101686986B1 (ko) * 2014-07-28 2016-12-16 에스케이케미칼주식회사 류프로라이드를 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
CA3055762A1 (en) 2017-03-31 2018-10-04 Progenity, Inc. Localization systems and methods for an ingestible device
US11253498B2 (en) * 2017-06-01 2022-02-22 Nexyon Biotech Co., Ltd. Pharmaceutical composition for treatment of bone-related disease
WO2019110688A1 (en) * 2017-12-05 2019-06-13 Ferring B.V. A composition comprising degarelix for use in the treatment of breast cancer
WO2023150267A1 (en) * 2022-02-03 2023-08-10 Maison Amori Oqvpo Llc Methods, compositions and uses for treating cancer by providing medications that induce targeted tumor cell mitosis before providing chemotherapy or radiation and kits therefor
WO2025219964A1 (en) * 2024-04-19 2025-10-23 J Dental Care Srl Composition for use in the treatment of perimenopausal and post-menopausal symptomatology and in the combined hormonal contraceptive treatment

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB9603325D0 (en) 1996-02-16 1996-04-17 Imperial College A compound
GB9625334D0 (en) 1996-12-05 1997-01-22 Imperial College Compound
GB9118478D0 (en) 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
GB9118465D0 (en) 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
ATE264106T1 (de) * 1994-11-22 2004-04-15 Balance Pharmaceuticals Inc Verfahren zur empfängnisverhütung
GB9807779D0 (en) 1998-04-09 1998-06-10 Ciba Geigy Ag Organic compounds
JP4320089B2 (ja) * 1999-07-06 2009-08-26 あすか製薬株式会社 フェニルスルファメート誘導体
CO5261573A1 (es) 1999-11-19 2003-03-31 Novartis Ag Derivados de benzoxa y bezotiazol, compuesto y composicion farmaceutica que los contiene y proceso para la preparacion de la mencionada composicion
GB0020498D0 (en) 2000-08-18 2000-10-11 Sterix Ltd Compound
GB0025788D0 (en) 2000-10-20 2000-12-06 Sterix Ltd Use
JP2004521951A (ja) * 2001-07-13 2004-07-22 シエーリング アクチエンゲゼルシャフト Ｈｒｔのためのドロスピレノン及びエストロゲンスルファメートの組み合わせ
AR037097A1 (es) 2001-10-05 2004-10-20 Novartis Ag Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
DE60209811T2 (de) 2001-10-18 2006-10-12 Sterix Ltd., Slough Steroidale verbindungen zur inhibierung von steroidsulfatasen
AU2002339192A1 (en) 2001-11-21 2003-06-10 Sterix Limited 1,2,4-triazole derivatives containing a sulphamate group as aromatase inhibitors
PE20040167A1 (es) 2002-03-28 2004-05-26 Novartis Ag Amidas del acido sulfamico
CA2501556A1 (en) * 2002-10-09 2004-04-29 Kyowa Hakko Kogyo Co., Ltd. Remedy for hormone-dependent cancer
AR041952A1 (es) 2002-11-14 2005-06-01 Novartis Ag N-sulfonilaminotiazol
CN101508691A (zh) * 2003-05-16 2009-08-19 特拉梅克斯实验室 用作类固醇硫酸酯酶抑制剂的氨基磺酸苯并噻吩酯衍生物
EP1624878B1 (en) * 2003-05-22 2006-09-27 Pantarhei Bioscience B.V. Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain
JP4834557B2 (ja) 2003-12-15 2011-12-14 ラボラトワール テラメックス １−ｎ−フェニルアミノ−１ｈ−イミダゾール誘導体及びこれを含む医薬組成物
GB0411562D0 (en) 2004-05-24 2004-06-23 Sterix Ltd Compound
GB0412492D0 (en) 2004-06-04 2004-07-07 Sterix Ltd Compound
GB0505541D0 (en) 2005-03-17 2005-04-27 Novartis Ag Organic compounds
GB0525323D0 (en) 2005-12-13 2006-01-18 Sterix Ltd Compound

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160076556A (ko) 2014-12-23 2016-07-01 주식회사 젬백스앤카엘 난소 기능 보존용 펩티드 및 이를 포함하는 조성물

Also Published As

Publication number Publication date
US20100204146A1 (en) 2010-08-12
CA2698814A1 (en) 2009-03-26
JP5543920B2 (ja) 2014-07-09
BRPI0817045A2 (pt) 2015-03-24
WO2009037539A2 (en) 2009-03-26
EP2207544A2 (en) 2010-07-21
JP2010539153A (ja) 2010-12-16
WO2009037539A3 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
KR20100068287A (ko) 폐경기 전 여성의 에스트로겐 의존성 질환의 치료
Felberbaum et al. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix.
TWI477276B (zh) 抗黃體素給藥方案
EP2114412B1 (en) Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
AU2017336338B2 (en) Methods of treating female infertility
KR20110021709A (ko) 자궁 섬유종의 치료를 위한 울리프리스탈의 용도
KR20090067198A (ko) 자궁내막 증식을 억제하는 조성물과 방법
Huang Medical treatment of endometriosis
Catchpole et al. Reproduction in the rhesus monkey, Macaca mulatta
EP3363500A1 (en) Method for treating gynecological diseases
US20080255053A1 (en) Method for the therapeutic management of endometriosis
SK3752002A3 (en) Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
EP1455831B1 (en) Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
EA011310B1 (ru) Однократная доза ингибитора ароматазы для лечения бесплодия
Bromer et al. Medical treatment options for leiomyomas
Critchley et al. Endometrial effects of hormonal contraception
Cameron et al. 5 Anti-progesterones: background and clinical physiology
GABCIA et al. EFFECTS OF THREE 19-NOR STEROIDS ON HUMAN OVULATION AND MENSTRUATION
Patel 6 Hysteroscopic Implications
US20020002153A1 (en) Pharmaceutical preparations for treating side effects during and/or after gnrha therapy
Ito et al. LIMITED EFFECTS OF ANTIANDROGENS AND GONADOTROPIN-RELEASING HORMONE AGONIST ON TRANSPLANTABLE HUMAN PROSTATIC CANCER HONDA

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100416

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130709

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140902

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150124

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140902

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I